Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer chemotherapy.

× No keyword cloud information.

11 in total

1. Receptor mobility and receptor-cytoplasmic interactions in lymphocytes.

Authors: G M Edelman; I Yahara; J L Wang
Journal: Proc Natl Acad Sci U S A Date: 1973-05 Impact factor: 11.205

2. Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

Authors: Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee
Journal: Invest New Drugs Date: 2015-12-21 Impact factor: 3.850

3. Inhibition by colchicine of the mitogenic stimulation of lymphocytes prior to the S phase.

Authors: J L Wang; G R Gunther; G M Edelman
Journal: J Cell Biol Date: 1975-07 Impact factor: 10.539

4. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

Authors: Weiwei Wang; Hangxiao Zhang; Xumin Wang; Jordan Patterson; Philip Winter; Kathryn Graham; Sunita Ghosh; John C Lee; Christos D Katsetos; John R Mackey; Jack A Tuszynski; Gane Ka-Shu Wong; Richard F Ludueña
Journal: Protoplasma Date: 2016-12-09 Impact factor: 3.356

5. Precipitation of proteins by vinblastine and calcium ions.

Authors: L Wilson; J Bryan; A Ruby; D Mazia
Journal: Proc Natl Acad Sci U S A Date: 1970-07 Impact factor: 11.205

6. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.

Authors: L J Wilkoff; D A Dulmadge; W R Laster; D P Griswold
Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333

Cancer chemotherapy.

1. Receptor mobility and receptor-cytoplasmic interactions in lymphocytes.

2. Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin.

3. Inhibition by colchicine of the mitogenic stimulation of lymphocytes prior to the S phase.

4. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.

5. Precipitation of proteins by vinblastine and calcium ions.

6. Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine.

7. Experimental investigations on a sequential combination chemotherapy protocol.

8. Microbial transformation of N-methylcolchiceinamide.

Review 9. Imidazoles as potential anticancer agents.

10. Methotrexate and the need for continued research.